Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136265

Published: 2020

Journal Articles

Elucidation of Autoinflammatory Mechanism in Pigt-PNH

Makiko Osato, MS, Yoshiko Murakami, MD PhD, Shogo Murata, MD PhD, Jun-Ichi Nishimura, MD PhD, Yasutaka Ueda, MD PhD, Taroh Kinoshita, PhD, Yuzuru Kanakura, MD PhD

Blood (2017) 130 (Supplement 1): 2201.

https://doi.org/10.1182/blood.V130.Suppl_1.2201.2201

Published: 2017

Journal Articles

Paroxysmal Nocturnal Hemoglobinuria Caused By Pigt Mutations; Atypical PNH

Yoshiko Murakami, MDPhD, Michi Kawamoto, MD, Norimitsu Inoue, MD PhD, Makiko Osato, DS, Shogo Murata, MD PhD, Sho Murase, MD, Hajime Yoshimura, MD, Yasutaka Ueda, MD PhD, Jun-Ichi Nishimura, MD PhD, Yuzuru Kanakura, MD PhD, Nobuo Kohara, MD, Taroh Kinoshita, PhD

Blood (2016) 128 (22): 2450.

https://doi.org/10.1182/blood.V128.22.2450.2450

Published: 2016

Journal Articles

Analysis of 3 Year Post Marketing Surveillance of Eculizumab in Japan

Blood (2014) 124 (21): 4870.

https://doi.org/10.1182/blood.V124.21.4870.4870

Published: 2014

Journal Articles

Inherited GPI-Anchor Deficiencies Caused By The Hypomorphic Mutations In PIG A gene: Comparison To Paroxysmal Nocturnal Hemogrobinuria

Yoshiko Murakami, MD, PhD, Mitsuhiro Kato, Hirotomo Saitsu, Kenjiro Kikuchi, Shuei Watanabe, Mizue Iai, Ryuki Matsuura, Rumiko Takayama, Chihiro Ohba, Shin-ichiro Hamano, Hitoshi Osaka, Kiyoshi Hayasaka, Naomichi Matsumoto, Taroh Kinoshita, PhD

Blood (2013) 122 (21): 3701.

https://doi.org/10.1182/blood.V122.21.3701.3701

Published: 2013

Journal Articles

A Rare Genetic Polymorphism In C5 Confers Poor Response To The Anti-C5 Monoclonal Antibody Eculizumab In 11 Japanese Patients With PNH

Blood (2013) 122 (21): 3709.

https://doi.org/10.1182/blood.V122.21.3709.3709

Published: 2013

Journal Articles

A Rare Genetic Polymorphism in C5 Confers Poor Response to the Anti-C5 Monoclonal Antibody Eculizumab by Nine Japanese Patients with PNH

Jun-ichi Nishimura, MD, PhD, Masaki Yamamoto, MD, Shin Hayashi, MD, PhD, Kazuma Ohyashiki, MD, Kiyoshi Ando, MD, Hideyoshi Noji, MD, PhD, Kunio Kitamura, MD, Tetsuya Eto, MD, Toshihiko Ando, MD, Masayoshi Masuko, MD, PhD, Hirohiko Shibayama, Masakazu Hase, PhD, Li Lan, Paul Tamburini, Johji Inazawa, MD, PhD, Taroh Kinoshita, PhD, Yuzuru Kanakura, MD, PhD

Blood (2012) 120 (21): 3197.

https://doi.org/10.1182/blood.V120.21.3197.3197

Published: 2012

Journal Articles

Crucial Role of Complement Receptor Type 1 On the Accumulation of Complement Component 3 On Erythrocytes in Patients with PNH Treated with Eculizumab

Masaki Yamamoto, MD, Jun-ichi Nishimura, MD, PhD, Makiko Oosato, Satoru Hayashi, Yoshiko Murakami, MD, PhD, Taroh Kinoshita, PhD, Yuzuru Kanakura, MD, PhD

Blood (2012) 120 (21): 988.

https://doi.org/10.1182/blood.V120.21.988.988

Published: 2012

Journal Articles

Release of Alkaline Phosphatase Caused by PIGV Mutations In Patients with Hyperphosphatasia-Mental Retardation Syndrome (HPMR), a Recently Found Second Inherited GPI Anchor Deficiency.

Yoshiko Murakami, MD, PhD, Peter M Krawitz, MD, PhD, Peter N Robinson, MD, PhD, Stefan Mundlos, MD, PhD, Yusuke Maeda, MD, PhD, Taroh Kinoshita, PhD

Blood (2010) 116 (21): 2031.

https://doi.org/10.1182/blood.V116.21.2031.2031

Published: 2010

Journal Articles

Expression of HMGA2 In Blood Cells From Patients with Paroxysmal Nocturnal Hemoglobinuria

Yoshiko Murakami, MD, PhD, Norimitsu Inoue, MD, PhD, Tsutomu Shichishima, MD, PhD, Hideyoshi Noji, MD, PhD, Jun-Ichi Nishimura, MD, PhD, Yuzuru Kanakura, MD, PhD, Taroh Kinoshita, PhD

Blood (2010) 116 (21): 4242.

https://doi.org/10.1182/blood.V116.21.4242.4242

Published: 2010

Journal Articles

Chronic Renal Insufficiency in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Improvement with Eculizumab Treatment in the Long-Term Follow-up of the AEGIS Study.

Yuzuru Kanakura, MD, PhD, Kazuma Ohyashiki, MD, PhD, Tsutomu Shichishima, MD, PhD, Shinichiro Okamoto, MD, PhD, Kiyoshi Ando, MD, PhD, Haruhiko Ninomiya, MD, PhD, Tatsuya Kawaguchi, MD, PhD, Shinji Nakao, MD, PhD, Hideki Nakakuma, MD, PhD, Jun-ichi Nishimura, MD, PhD, Taroh Kinoshita, PhD, Camille Bedrosian, MD, Marye Ellen Valentine, MS, Keiya Ozawa, MD, PhD, Mitsuhiro Omine, MD

Blood (2009) 114 (22): 1980.

https://doi.org/10.1182/blood.V114.22.1980.1980

Published: 2009

Journal Articles

Wnt Pathway Is Upregulated in Blood Cells From Patients with Paroxysmal Nocturnal Hemoglobinuria.

Yoshiko Murakami, Norimitsu Inoue, Tsutomu Shichishima, MD, PhD, Hideyoshi Noji, MD, PhD, Jun-ichi Nishimura, MD, PhD, Yuzuru Kanakura, MD, PhD, Taroh Kinoshita, PhD

Blood (2009) 114 (22): 1987.

https://doi.org/10.1182/blood.V114.22.1987.1987

Published: 2009

Journal Articles

Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria: AEGIS Phase II Clinical Study Results.

Yuzuru Kanakura, MD, PhD, Kazuma Ohyashiki, MD, Tsutomu Shichishima, MD, PhD, Shinichiro Okamoto, MD, PhD, Kiyoshi Ando, MD, Haruhiko Ninomiya, MD, PhD, Tatsuya Kawaguchi, MD, PhD, Shinji Nakao, MD, Hideki Nakakuma, MD, PhD, Jun-Ichi Nishimura, MD, PhD, Taroh Kinoshita, PhD, Camille Bedrosian, MD, Marye Ellen Valentine, MS, Keiya Ozawa, MD, PhD, Mitsuhiro Omine, MD

Blood (2008) 112 (11): 3438.

https://doi.org/10.1182/blood.V112.11.3438.3438

Published: 2008

Journal Articles

Expression of HMGA2 in Blood Cells from Patients with Paroxysmal Nocturnal Hemoglobinuria.

Yoshiko Murakami, MD, PhD, Rieko Ohta, PhD, Norimitsu Inoue, MD, PhD, Hideyoshi Noji, MD, PhD, Tsutomu Shichishima, MD, PhD, Jun-Ichi Nishimura, MD, PhD, Yuzuru Kanakura, MD, PhD, Taroh Kinoshita, PhD

Blood (2008) 112 (11): 3439.

https://doi.org/10.1182/blood.V112.11.3439.3439

Published: 2008

Journal Articles

Targeted Molecular Therapy for Inherited Glycosylphosphatidylinositol Deficiency.

A.M. Almeida, MD, Y. Murakami, PhD, A. Baker, MD, Y. Maeda, PhD, Irene Roberts, PhD, Taroh Kinoshita, PhD, D.M. Layton, MD, A. Karadimitris, PhD

Blood (2006) 108 (11): 487.

https://doi.org/10.1182/blood.V108.11.487.487

Published: 2006

Journal Articles

Clonal Expansion in Paroxysmal Nocturnal Hemoglobinuria (PNH): Expression of Mutant HMGA2 Suggests That PNH Is a Benign Tumor of the Bone Marrow.

Norimitsu Inoue, MD, PhD, Tomohisa Izui, MD, Yoshiko Murakmai, MD, PhD, Yuichi Endo, PhD, Jun-ichi Nishimura, MD, PhD, Yuzuru Kanakura, MD, PhD, Gabrielle Meyers, MD, Carl Wittwer, MD, PhD, Zhong Chen, MD, William Babcock, MD, Debra Frei-Lahr, MD, Charles Parker, MD, Taroh Kinoshita, PhD

Blood (2005) 106 (11): 3533.

https://doi.org/10.1182/blood.V106.11.3533.3533

Published: 2005

NARROW

An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial

Elucidation of Autoinflammatory Mechanism in Pigt-PNH

Paroxysmal Nocturnal Hemoglobinuria Caused By Pigt Mutations; Atypical PNH

Analysis of 3 Year Post Marketing Surveillance of Eculizumab in Japan

Inherited GPI-Anchor Deficiencies Caused By The Hypomorphic Mutations In PIG A gene: Comparison To Paroxysmal Nocturnal Hemogrobinuria

A Rare Genetic Polymorphism In C5 Confers Poor Response To The Anti-C5 Monoclonal Antibody Eculizumab In 11 Japanese Patients With PNH

A Rare Genetic Polymorphism in C5 Confers Poor Response to the Anti-C5 Monoclonal Antibody Eculizumab by Nine Japanese Patients with PNH

Crucial Role of Complement Receptor Type 1 On the Accumulation of Complement Component 3 On Erythrocytes in Patients with PNH Treated with Eculizumab

Release of Alkaline Phosphatase Caused by PIGV Mutations In Patients with Hyperphosphatasia-Mental Retardation Syndrome (HPMR), a Recently Found Second Inherited GPI Anchor Deficiency.

Expression of HMGA2 In Blood Cells From Patients with Paroxysmal Nocturnal Hemoglobinuria

Chronic Renal Insufficiency in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Improvement with Eculizumab Treatment in the Long-Term Follow-up of the AEGIS Study.

Wnt Pathway Is Upregulated in Blood Cells From Patients with Paroxysmal Nocturnal Hemoglobinuria.

Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria: AEGIS Phase II Clinical Study Results.

Expression of HMGA2 in Blood Cells from Patients with Paroxysmal Nocturnal Hemoglobinuria.

Targeted Molecular Therapy for Inherited Glycosylphosphatidylinositol Deficiency.

Clonal Expansion in Paroxysmal Nocturnal Hemoglobinuria (PNH): Expression of Mutant HMGA2 Suggests That PNH Is a Benign Tumor of the Bone Marrow.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only